GlaxoSmithKline Stock Forecast, Price & News

GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

Is GlaxoSmithKline a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 1 sell rating, 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GlaxoSmithKline stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View analyst ratings for GlaxoSmithKline or view top-rated stocks.

How has GlaxoSmithKline's stock price been impacted by Coronavirus (COVID-19)?

GlaxoSmithKline's stock was trading at $39.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GSK shares have increased by 3.0% and is now trading at $41.06.
View which stocks have been most impacted by COVID-19.

Are investors shorting GlaxoSmithKline?

GlaxoSmithKline saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 12,330,000 shares, a drop of 20.9% from the October 31st total of 15,580,000 shares. Based on an average daily volume of 4,130,000 shares, the short-interest ratio is currently 3.0 days. Approximately 0.5% of the shares of the stock are short sold.
View GlaxoSmithKline's Short Interest.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release its next quarterly earnings announcement on Wednesday, February 2nd 2022.
View our earnings forecast for GlaxoSmithKline.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) released its quarterly earnings results on Wednesday, October, 27th. The pharmaceutical company reported $1.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.80 by $0.21. The pharmaceutical company had revenue of $12.51 billion for the quarter, compared to the consensus estimate of $11.92 billion. GlaxoSmithKline had a trailing twelve-month return on equity of 26.27% and a net margin of 13.01%.
View GlaxoSmithKline's earnings history.

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Friday, October 29th. Stockholders of record on Friday, November 19th will be paid a dividend of $0.5234 per share on Thursday, January 13th. This represents a $2.09 dividend on an annualized basis and a yield of 5.10%. The ex-dividend date of this dividend is Thursday, November 18th. This is a boost from GlaxoSmithKline's previous quarterly dividend of $0.52.
View GlaxoSmithKline's dividend history.

Is GlaxoSmithKline a good dividend stock?

GlaxoSmithKline pays an annual dividend of $2.06 per share and currently has a dividend yield of 5.03%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. GlaxoSmithKline does not yet have a strong track record of dividend growth. The dividend payout ratio of GlaxoSmithKline is 87.29%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, GlaxoSmithKline will have a dividend payout ratio of 63.19% next year. This indicates that GlaxoSmithKline will be able to sustain or increase its dividend.
View GlaxoSmithKline's dividend history.

What guidance has GlaxoSmithKline issued on next quarter's earnings?

GlaxoSmithKline issued an update on its FY 2021 earnings guidance on Wednesday, November, 3rd. The company provided EPS guidance of $1.560-$1.590 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.860. The company issued revenue guidance of -.

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the following people:

• Emma N. Walmsley, Chief Executive Officer & Executive Director
• Iain James Mackay, Chief Financial Officer & Executive Director
• Jon Ellis, VP & Head-Technology Business Development
• Karenann K. Terrell, Chief Digital & Technology Officer
• Hal V. Barron, Executive Director & Chief Scientific Officer

Who are some of GlaxoSmithKline's key competitors?

Some companies that are related to GlaxoSmithKline include Johnson & Johnson (JNJ), Roche (RHHBY), Pfizer (PFE), Novo Nordisk A/S (NVO), Eli Lilly and (LLY), Abbott Laboratories (ABT), AbbVie (ABBV), Merck & Co., Inc. (MRK), Novartis (NVS), AstraZeneca (AZN), Sanofi (SNY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), CSL (CSLLY) and Regeneron Pharmaceuticals (REGN).
View all of GSK's competitors.

What other stocks do shareholders of GlaxoSmithKline own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and NVIDIA (NVDA).

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by a variety of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.66%), Black Creek Investment Management Inc. (0.38%), Renaissance Technologies LLC (0.35%), Hotchkis & Wiley Capital Management LLC (0.34%), JTC Employer Solutions Trustee Ltd (0.23%) and BNP Paribas Arbitrage SA (0.22%).
View institutional ownership trends for GlaxoSmithKline.

Which major investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including JTC Employer Solutions Trustee Ltd, Boston Common Asset Management LLC, SG Americas Securities LLC, Hotchkis & Wiley Capital Management LLC, Grantham Mayo Van Otterloo & Co. LLC, Macquarie Group Ltd., Jane Street Group LLC, and John G Ullman & Associates Inc..
View insider buying and selling activity for GlaxoSmithKline or view top insider-selling stocks.

Which major investors are buying GlaxoSmithKline stock?

GSK stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Two Sigma Advisers LP, Arrowstreet Capital Limited Partnership, Black Creek Investment Management Inc., The Manufacturers Life Insurance Company , Renaissance Technologies LLC, Bank of New York Mellon Corp, and Fisher Asset Management LLC.
View insider buying and selling activity for GlaxoSmithKline or or view top insider-buying stocks.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $41.06.

How much money does GlaxoSmithKline make?

GlaxoSmithKline has a market capitalization of $110.56 billion and generates $43.79 billion in revenue each year. The pharmaceutical company earns $7.38 billion in net income (profit) each year or $2.36 on an earnings per share basis.

How many employees does GlaxoSmithKline have?

GlaxoSmithKline employs 94,066 workers across the globe.

When was GlaxoSmithKline founded?

GlaxoSmithKline was founded in 2000.

What is GlaxoSmithKline's official website?

The official website for GlaxoSmithKline is www.gsk.com.

Where are GlaxoSmithKline's headquarters?

GlaxoSmithKline is headquartered at 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The pharmaceutical company can be reached via phone at 442080475000, via email at [email protected], or via fax at 44-20-8047-7807.